IBR-Dormin - in-cosmetics Asia

IBR-Dormin
Patented technology by IBR Ltd.
®
benefits for oily, acne prone skin
IBR-DORMIN®, SEBOCYTES, SEBUM AND ACNE
Introduction
IBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) is a natural aqueous extract
from Narcissus bulbs in their dormant stage that is able to slow cell proliferation in a
reversible and general manner. Among cell types affected are also keratinocytes and
sebocytes. IBR-Dormin® captures and transform flower bulbs dormancy and beauty
to the skin.
Sebocytes and Sebum: sebum is an oily/waxy matter that is secreted by the sebaceous
glands and produced by the specialized cells named sebocytes. The sebum is used to
lubricate and water proof the skin and hair of mammals. In humans they are found in greater
abundance in the face and scalp but also distributed throughout all skin sites. There are several
medical conditions related to excess production of sebum that include seborrhea and acne.
Acne develops as a result of blockages in follicles or comedones as a result of enlargement
and clogging of sebaceous glands and increased sebum production. Under these conditions,
the naturally occurring bacteria, Propionibacterium acnes that nourish on the sebum and cell
debris can cause inflammation expressed in lesions leading to scars and local pigmentation.
It’s been suggested that reduction in sebum production to reduce total oils in the skin may
contribute to preventing and treating acne outbreaks.
A way to control sebum production could therefore be reduction in sebocytes proliferation that
leads to reduced production and secretion of sebum thereby reducing oiliness of the skin as
suggest to be controlled by IBR-Dormin®.
in vitro
Being able to slowdown proliferation of cells in a non-specific manner, IBR- Dormin®
was able to affect sebocytes proliferation while using primary sebocyte cultures.
Using 0.05%-0.4% IBR-Dormin® for five days, a dose responsive reduction in
sebocyte number, relative to untreated control, was observed, ranging from
48.9-89.3%, respectively.
CLINICAL STUDY
Evaluation of the safety and efficacy of a gel product in the reduction of oiliness
in a randomized, double blind, parallel treatment, placebo controlled trial.
Test Product:
Gel Product with 1.5% IBR-Dormin - Code H
Gel Product with 1.5% IBR-Dormin + 0.5% Salicylic acid - Code F
Gel Product with 0.5% Salicylic acid - Code T
Commercial Benchmark Cream (CBC) - Code M
Background: This was a double blind, single center study. There were four cells in the study
with each cell using one test product.
Subjects: 80 subjects (20 for each product). Male or female, 13-20 years old and in general
good health. Subjects had oily facial skin (Sebumeter reading of 180 and above). There were
no adverse events reported during the study.
Procedure:
The study lasted 8 weeks (2 weeks washout + 6 weeks treatment).
Instrumental assessment:
Sebumeter Measurements
Expert assessment for:
Oiliness
Open comedones
Blackheads
Subject Self Assessment:
Subject Self Assessment for parameters like oiliness, shine, dryness, flakiness and irritation.
All assessments were taken at baseline, day 3, week 1, week 2, week 4 and week 6.
Assessments were graded using a 1 to 10 scale (1= very unfavourable, 10= very favourable).
FineSchmeckers
IBR-Dormin
®
RESULTS
Open Comedones:
Instrumental Assessment
Significant difference wrt
baseline is observed in case
of IBR-Dormin with sal acid
(from week 1), CBC (from
week 2) and IBR-Dormin
alone (from week 4)
Placebo shows no significant
improvement wrt baseline.
IBR-Dormin + sal acid shows significant reduction in sebumeter readings wrt baseline from day 3 until week 4.
CBC shows significant difference wrt baseline from day 3 until week 2.
Placebo shows significant difference only at day 3 and not at subsequent timepoints.
Dermatological Assessment
Oiliness:
Significant decrease was
observed in oiliness for both
of the IBR- Dormin
formulations and CBC from
day 3 onwards until week 6.
Placebo shows significant
decrease from week 1.
However no significant
difference observed
between the products.
Oiliness (% change vs. baseline)
Consumer Self Assessment
Blackheads:
Significant change is
observed in case of
IBR-Dormin + sal acid and
CBC formulations from Week
1 onwards and this is
maintained until week 6. IBRDormin without sal acid only
formulation shows significant
change from week 2 onwards.
No significant change is
observed in case of placebo
wrt baseline. No significant
difference observed between
the products.
Subjects perceive significant improvement in oiliness vs baseline for all products except placebo from
day 3 onwards.
In case of placebo significant improvement is seen from week 1.
Subjects also perceive improvement in shine for 1.5% IBR-Dormin from week 1. They also perceive that
1.5% IBR-Dormin and CBC formulation make their skin feel less dry from week 1.
1.5% IBR-Dormin formulation is also perceived to reduce flaky patches on skin from week 4.
Both CBC and placebo is perceived to improve softness from week 2.
CBC is found to improve overall appearance from week 1, while 1.5% IBR- Dormin is found to improve
overall appearance from week 2.
CONCLUSIONS
IBR-Dormin® (INCI: Narcissus Tazetta Bulb Extract) ability to control and reduce cell proliferation of
various types of cells including sebocytes may assist in reducing skin oiliness, shine, pore size and
improves overall appearance. Together with ingredients that can control the acne related bacterial
growth one may significantly affect acne outbreaks as well as post acne scaring and pigmentation.
IBR-DORMIN® CONTROLS SEBUM, REDUCES SKIN
OILINESS, SHINE AND PORE SIZE THEREBY BEAUTIFY THE
SKIN AND ASSISTS CONTROLLING ACNE OUTBREAKS
INNOVATION INSPIRED BY NATURE
Business Development
& Marketing:
Tel: +49-30-80589698
Fax: +49-30-80589704
[email protected]
DISCLAIMER: This catalog is designed to provide R&D and product development information on ingredients supplied by IBR as raw materials
for cosmetic, food and other industries. This catalog is not designed to satisfy information requirements of consumers making use of the final
product. The information contained herein is not applicable to, nor intended to satisfy, the legal/regulatory requirements of all countries.
Nothing in this catalog is to be construed as the making of claims regarding the use of finished consumer products comprising IBR
ingredients. Each manufacturer is responsible for ensuring that the claims made for and use of its products comply with the regulatory
requirement of the countries in which it markets its products.
Please be advised that you may display IBR trademarks, trade names, copyright, images and other IBR information only in promotional
material and packaging for your products that contain IBR products purchased from IBR or an authorized IBR distributor and only if your
products use IBR products in the concentration for which efficacy has been established. IBR’s products are protected by patents, patent
applications, copyrights and trade secrets and nothing in this catalog gives you any rights under those patents, patent applications,
copyrights or trade secrets. Your right to use IBR trademarks, trade names, copyright, images and other IBR information described in this
paragraph is non-exclusive. In addition, upon your ceasing to use IBR products in your products, the right to use IBR trademarks, trade
names, copyright, images and other information described in this paragraph shall immediately terminate and you will cease all such usage.
© IBR. All Rights Reserved
FineSchmeckers
Office & Laboratory:
4 Pekeris St., Tamar Science
Park, Rehovot 7670204, Israel
Tel: +972-8-9465433
Fax: +972-8-9472174
[email protected]